ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET).
The presentation will be available through a live webcast and archived at investor.myriad.com.Â
About Myriad Genetics  Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.Â
Investor Contact  Matt Scalo  (801) 584-3532  IR@myriad.com Â
Media Contact  Kate Schraml (224) 875-4493 PR@myriad.com 
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know.
